Replimune Group, Inc. REPL R2K
Healthcare · Biotechnology · United States
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
READ MORE ›$8.69
-3.23% 1Y
Market & Price
Market Cap
$717.56M
Current Price
$8.69
High / Low (52W)
$12.63 / $1.70
Beta
0.12
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$2.64
Price to Book
3.29
P/S
-
EV/EBITDA
-1.65
Dividend Yield
-
Profitability & Returns
ROCE
-48.87%
ROE
-90.88%
ROA
-43.24%
Profit Margin
0.00%
Op Margin
0.00%
EPS (Latest Qtr)
$-0.77
EPS (TTM)
$-3.44
Balance Sheet & Liquidity
Debt/Equity
0.36
Quick Ratio
5.43
Current Ratio
5.60
Debt
$76.35M
Total Assets
$551.33M
Current Assets
$495.88M
Working Capital
$433.52M
Ownership
Promoter Holding
2.62%
Chg in Prom Hold
-
FII / Inst Holding
97.48%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$524.77M
Total Revenue (TTM)
-
EBITDA
$-318.88M
Free Cash Flow
$-172.75M
Operating Cash Flow
$-277.91M
Shares Outstanding
82.57M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-
Profit 5Y
-36.50%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -36.5% CAGR over 5 years.
- Trading 31.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 76 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | REPL Replimune Group, Inc. R2K | 8.69 | - | $717.56M | - | -48.87% | -90.88% | - | -36.50% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Jun 2022 | Sep 2022 | Dec 2022 | Jun 2023 | Sep 2023 | Dec 2023 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 65.64M | 78.78M | 90.00M | 83.91M | 71.53M |
| Operating Income | -3.18M | -4.26M | -4.73M | - | -5.88M | -7.10M | -10.14M | - | -10.91M | -12.24M | -16.66M | - | -17.83M | -19.66M | -20.27M | - | -27.38M | -29.25M | -29.70M | -40.88M | -41.58M | -41.63M | -55.65M | -63.83M | -56.54M | -57.37M | - | -65.64M | -78.78M | -90.00M | -83.91M | -71.53M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -62.79M | -71.40M | -83.82M | -80.25M | -68.41M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.98M | 1.99M | 2.00M | 2.01M | 1.98M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -65.77M | -74.24M | -86.69M | -83.10M | -71.24M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 575.00K | -107.00K | - | - | -311.00K |
| Net Income | -3.55M | -4.66M | -4.35M | -7.14M | -10.04M | -6.46M | -7.67M | -6.66M | -9.51M | -11.14M | -16.19M | -15.79M | -17.49M | -20.09M | -21.78M | -21.50M | -27.31M | -29.36M | -29.67M | -42.25M | -43.10M | -39.69M | -49.55M | -60.04M | -51.12M | -53.77M | - | -66.34M | -74.13M | -86.69M | -83.10M | -70.93M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -0.44 | -0.46 | -0.44 | - | -0.53 | -0.56 | -0.57 | -0.78 | -0.79 | -0.69 | -0.75 | -0.90 | -0.77 | -0.78 | -0.68 | -0.79 | - | -0.95 | -0.90 | -0.77 |
| R&D Expense | 2.29M | 3.15M | 3.57M | - | 3.94M | 4.96M | 7.86M | - | 7.46M | 8.17M | 11.95M | - | 12.16M | 14.05M | 14.32M | - | 18.55M | 19.90M | 19.35M | 29.48M | 28.83M | 30.26M | 40.44M | 49.10M | 42.85M | 42.97M | 43.45M | 48.00M | - | 57.84M | 57.88M | 53.14M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | 115.14M | 174.17M | 232.85M | 259.85M |
| Operating Income | -9.65M | -19.23M | -30.95M | -56.20M | -79.95M | -115.14M | -174.17M | -232.85M | -259.85M |
| EBITDA | - | - | - | - | - | -113.67M | -167.39M | -206.07M | -235.43M |
| Interest Expense | - | - | - | - | - | 2.22M | 4.16M | 6.66M | 7.89M |
| Pretax Income | - | - | - | - | - | -118.04M | -174.00M | -215.39M | -246.83M |
| Tax Provision | - | - | - | - | - | 0 | 288.00K | 408.00K | 468.00K |
| Net Income | -7.70M | -19.70M | -30.83M | -52.62M | -80.87M | -118.04M | -174.28M | -215.79M | -247.30M |
| Diluted EPS | - | - | - | - | -1.75 | -2.26 | -2.99 | -3.24 | -3.07 |
| R&D Expense | 6.94M | 13.52M | 22.17M | 38.76M | 56.75M | 79.55M | 126.53M | 174.96M | 189.45M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -36.50% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -3.23% |
| 6 Months: | -8.81% |
| 3 Months: | +13.59% |
| 1 Month: | +265.13% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 65.15M | 154.33M | 234.10M | 543.10M | 461.19M | 646.59M | 487.72M | 551.33M |
| Current Assets | - | - | - | - | - | 403.98M | 592.60M | 433.67M | 495.88M |
| Cash & Equivalents | - | 17.58M | 25.70M | 59.50M | 182.52M | 105.95M | 146.59M | 74.46M | 111.12M |
| Inventory | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | 3.06M | 2.94M | 4.92M | 3.73M |
| Total Liabilities | - | 6.86M | 16.47M | 50.38M | 44.37M | 49.96M | 91.30M | 113.21M | 135.49M |
| Current Liabilities | - | 5.16M | 9.88M | 11.87M | 14.55M | 20.76M | 33.83M | 40.44M | 62.36M |
| Long Term Debt | - | - | - | - | - | - | 28.65M | 44.81M | 46.38M |
| Total Debt | - | - | - | - | - | 32.84M | 60.76M | 75.87M | 76.17M |
| Total Equity | -11.52M | -28.07M | 137.86M | 183.72M | 498.73M | 411.23M | 555.29M | 374.51M | 415.84M |
| Shares Outstanding | - | - | - | - | - | 47.34M | 56.68M | 61.42M | 77.09M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.08M | -16.01M | -25.38M | -60.55M | -61.39M | -82.18M | -128.05M | -185.47M | -192.25M |
| Investing Cash Flow | -238.00K | -44.05M | -65.94M | -5.23M | -188.78M | -1.81M | -142.50M | 97.20M | -23.80M |
| Financing Cash Flow | 15.00M | 54.75M | 101.39M | 100.17M | 372.46M | 6.60M | 311.30M | 16.28M | 252.40M |
| Capital Expenditure | -238.00K | -136.00K | -2.60M | -6.54M | -2.39M | -2.34M | -2.27M | -5.66M | -6.69M |
| Free Cash Flow | -7.32M | -16.15M | -27.98M | -67.09M | -63.78M | -84.52M | -130.32M | -191.13M | -198.94M |
| Net Change in Cash | - | - | - | - | - | -77.39M | 40.75M | -71.98M | 36.35M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| ROE % | 66.9% | 70.2% | -22.4% | -28.6% | -16.2% | -28.7% | -31.4% | -57.6% | -59.5% |
| ROCE % | - | -32.1% | -21.4% | -25.3% | -15.1% | -26.1% | -28.4% | -52.1% | -53.1% |
Shareholding Pattern
Insiders
2.62%
Institutions
97.48%
Public Float
100.10%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Baker Bros. Advisors, LP | 13.38% | 11.05M | $95.98M |
| 2 | Price (T.Rowe) Associates Inc | 9.84% | 8.12M | $70.58M |
| 3 | RTW Investments LP | 8.91% | 7.36M | $63.93M |
| 4 | Blackrock Inc. | 7.56% | 6.24M | $54.22M |
| 5 | Suvretta Capital Management, LLC | 5.11% | 4.22M | $36.69M |
| 6 | State Street Corporation | 4.58% | 3.78M | $32.87M |
| 7 | FCPM III Services B.V. | 3.40% | 2.81M | $24.40M |
| 8 | Vanguard Capital Management LLC | 3.34% | 2.76M | $23.98M |
| 9 | Shaw D.E. & Co., Inc. | 2.83% | 2.34M | $20.30M |
| 10 | Goldman Sachs Group Inc | 2.76% | 2.28M | $19.79M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for REPL
No recent headlines available.